NASDAQ:LFCR - Nasdaq - US5147661046 - Common Stock - Currency: USD
LIFECORE BIOMEDICAL INC
NASDAQ:LFCR (2/4/2025, 8:00:02 PM)
After market: 5.94 0 (0%)5.94
+0.22 (+3.85%)
The current stock price of LFCR is 5.94 USD. In the past month the price decreased by -22.05%. In the past year, price decreased by -30.53%.
CHASKA, Minn., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and...
Company Seeking to Remove Convertible Preferred Stock Exchange Cap to Permit Potential Conversion of Series A Preferred Stock as Contemplated by the Series A Preferred Stock Terms
Company Seeking to Remove Convertible Preferred Stock Exchange Cap to Permit Potential Conversion of Series A Preferred Stock as Contemplated by the Series...
Company Believes it is Well Positioned for Mid-Term and Long-Term Growth asCurrent Capacity Continues to Support up to $300 Million in Annual Revenue ...
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
TMO | THERMO FISHER SCIENTIFIC INC | 26.56 | 222.07B | ||
DHR | DANAHER CORP | 28.71 | 155.30B | ||
A | AGILENT TECHNOLOGIES INC | 27.8 | 41.93B | ||
IQV | IQVIA HOLDINGS INC | 18.42 | 36.31B | ||
MTD | METTLER-TOLEDO INTERNATIONAL | 35.12 | 28.27B | ||
WAT | WATERS CORP | 36.03 | 24.37B | ||
WST | WEST PHARMACEUTICAL SERVICES | 48.97 | 23.97B | ||
ILMN | ILLUMINA INC | 71.79 | 19.70B | ||
ICLR | ICON PLC | 13.78 | 15.96B | ||
RVTY | REVVITY INC | 25.13 | 14.99B | ||
AVTR | AVANTOR INC | 22.46 | 14.98B | ||
TECH | BIO-TECHNE CORP | 40.53 | 11.53B |
Lifecore Biomedical, Inc. is a contract development and manufacturing organization, which engages in the provision of differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. The company is headquartered in Chaska, Minnesota and currently employs 524 full-time employees. The firm designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The firm offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. The company is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The firm uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.
LIFECORE BIOMEDICAL INC
3515 Lyman Boulevard
Chaska MINNESOTA US
Employees: 524
Company Website: https://www.lifecore.com/
Investor Relations: https://ir.lifecore.com/
Phone: 19523684300
The current stock price of LFCR is 5.94 USD.
The exchange symbol of LIFECORE BIOMEDICAL INC is LFCR and it is listed on the Nasdaq exchange.
LFCR stock is listed on the Nasdaq exchange.
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for LFCR, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of LFCR.
LFCR does not pay a dividend.
LFCR does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.59).
The outstanding short interest for LFCR is 7.45% of its float.
ChartMill assigns a fundamental rating of 2 / 10 to LFCR. Both the profitability and financial health of LFCR have multiple concerns.
Over the last trailing twelve months LFCR reported a non-GAAP Earnings per Share(EPS) of -0.59. The EPS decreased by 75.86% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -6.42% | ||
ROE | -27.42% | ||
Debt/Equity | 1.99 |
ChartMill assigns a Buy % Consensus number of 78% to LFCR. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of -304.88% and a revenue growth 2.52% for LFCR